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Highlights  
 In this study performed a comprehensive longitudinal genoprevalence analysis 
of 13 diverse Human polyomaviruses (HPyVs) using a novel multiplex assay in 
kidney transplant recipients (KTRs) with high level BK (BKPyV) and JC virus 
DNAemia and Polyomavirus associated nephropathy. 
 In total, we included 400 serum and 388 urine samples obtained pairwise from 
99 KTRs during the post-transplant follow-up.  
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 Three different recently discovered non-BKPyV/JCPyV HPyVs, Human 
Polyomavirus 9, Merkel cell Polyomavirus (MCPyV) and Trichodysplasia 
spinulosa associated Polyomavirus, were detected in 11 blood and 21 urine 
samples from 21 patients.  
 DNAemia of these viruses occurred frequently during high level BKPyV 
DNAemia and PVAN. However, no statistically significant increase of the 
detection frequency was observed due to progression of BKPyV replication for 
blood samples.  
 Of note, the detection rate of MCPyV in urine was significantly higher during 
BKPyV DNAemia in KTRs with histologically verified PVAN 
 
 
Abstract: Background: 
While the pathogenicity of the two initially identified Human Polyomaviruses (HPyVs), BK 
Virus (BKPyV) and JC Virus (JCPyV) has been intensely studied, there is only limited data, 
on whether the occurrences of the recently discovered HPyVs correlates with high level 
BKPyV replication and progression towards Polyomavirus associated nephropathy (PVAN). 
Methods:  
Therefore, we performed a comprehensive longitudinal genoprevalence analysis of 13 
HPyVs using a novel multiplex assay including 400 serum and 388 urine samples obtained 
from 99 kidney transplant recipients (KTRs), grouped by quantitative BKPyV DNA loads 
and evidence of manifest BKPyV associated disease (histologically verified PVAN, high 
urinary decoy cell levels and concurrent decrease of renal function). 
Results:  
In total, 3 different non-BKPyV/JCPyV HPyVs, Human Polyomavirus 9, Merkel Cell 
Polyomavirus (MCPyV) and Trichodysplasia Spinulosa associated Polyomavirus were 
detected in 11 blood and 21 urine samples from 21 patients. Although DNAemia of these 
viruses occurred more frequently during high level BKPyV DNAemia and PVAN, the 
increase of the detection frequency due to progression of BKPyV replication did not reach 
statistical significance for blood samples. The positive detection rate of MCPyV in urine, 
however, was significantly higher during BKPyV DNAemia in 19 KTRs of our cohort who 
suffered from histologically verified PVAN (p=0.005). In one individual with PVAN, 
continuous long-term shedding of MCPyV in urine was observed. 
Conclusion: 
 In our cohort the recently discovered HPyVs HPyV9, TSPyV and MCPyV emerged in blood 
from KTRs with variable kinetics, while detection of MCPyV DNAuria occurred more 
frequently during BKPyV DNAemia in patients with PVAN. 
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Introduction 
BK Virus (BKPyV) and JC virus (JCPyV) were isolated as first Human 
Polyomaviruses (HPyVs) from urine of a nephropathic kidney transplant recipient 
(KTR) and from brain tissue of a patient with progressive multifocal 
leukencephalopathy and named by the initials of the respective patients (1, 2).  
To date, the following additional HPyVs are known to exist: Karolinska Institute 
and Washington University Polyomaviruses, Merkel cell Polyomavirus (MCPyV), 
Trichodysplasia spinulosa associated Polyomavirus (TSPyV), Human 
Polyomaviruses 6, 7, 9, 12, Malawi Polyomavirus, Saint Louis Polyomavirus, New 
Jersey Polyomavirus and Lyon IARC polyomavirus, which has not yet been assigned 
to a polyomavirus species (3-7). 
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Prolonged and asymptomatic shedding of these viruses occurs in healthy 
individuals, and in immunocompromised individuals they may cause severe disease 
(3, 8). MCPyV was associated with development of Merkel cell carcinoma (9), while 
TSPyV can cause a rare follicular skin disease (10). For the recently discovered 
HPyVs no definitive association with any major clinical manifestation has been 
verified. 
BKPyV and JCPyV, in contrast, have been functionally linked with clinical 
manifestations in KTRs (11-13). Indeed, Polyomavirus associated nephropathy 
(PVAN) is a severe disease, that may affect up to 10% of all KTRs and cause allograft 
loss in 10% to 100% of affected patients (11-15). While BKPyV is the primary 
causative agent of PVAN, JCPyV can also trigger PVAN in rare cases (12, 15, 16).  
Thus, the question opens up whether the newly discovered HPyVs occur more 
frequently in KTRs with BKPyV-induced PVAN. So we performed a comprehensive 
genoprevalence analysis of 13 HPyVs in blood and urine samples collected pairwise 
from KTRs with BKPyV DNAemia with and without evidence for progression towards 
PVAN. 
 
Materials and Methods 
Patients and samples 
This retrospective study included 400 plasma and 388 urine samples from 99 
KTRs (35 female, 64 male; mean age: 57 years, range: 19-79), who received a kidney 
transplant between March 2008 and September 2014. Detailed clinical information is 
given in Supplemental Material and Methods and Supplemental Table 1. From each 
patient, plasma and urine samples were collected pairwise at the same day 
respectively due to virological routine post-transplant surveillance (386 sample pairs, 
14 plasma and 2 urine samples were acquired without corresponding samples). The 
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median number of samples per patient was 3 (plasma and urine) respectively. The 
median interval between sample acquisition post-transplant was 79 days for plasma 
and 84 days for urine (range: 11-561). Samples were acquired during the following 
periods post-transplant (plasma/urine): 0 (at transplantation): n= 5/4, post-transplant 
day 1-90: n=66/62, 91-180: n=107/102, 181-270: n=72/72, 271-360: n=46/47, 361-
450: n=24/22, 451-540: n=19/19, 541-630: n=13/13, 631-720: n=15/15, >720: 
n=33/32.  
The study protocol was approved by the ethics committee of the Medical 
University of Vienna (EK2064/2016). Since the samples had been acquired for 
virological diagnosis in the past, the ethics committee concluded that no written 
informed consent from patients was required (EK1035/2016). 
 
Quantitative BKPyV and JCPyV PCR  
In each urine and plasma sample BKPyV and JCPyV DNA was quantified due 
to routine surveillance post-transplant using a testing schedule and protocol included 
in Supplementary Material and Methods.  
 
DNA isolation for HPyV multiplex assay 
For HPyV multiplex assays DNA was isolated from EDTA-plasma by QIAmp 
Blood-Mini kit, and from urine by QIAamp Viral RNA kit (both Qiagen, Germany), 
according to the manufacturer’s instructions. Isolated DNA from 200μL EDTA-plasma 
was finally eluted into 100 μL AE buffer and DNA from 140μL urine was eluted into 
60μL of AVE buffer (both Qiagen, Germany). 
 
HPyV multiplex PCR 
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Viral DNA of each sample was measured using a novel bead-based multiplex 
PCR for 13 HPyVs, as described previously (17, 18). More detailed information is 
given in Supplementary Material and Methods.  
 
Bead-based suspension assay 
To semi-quantify all 13 HPyVs simultaneously, we applied bead-based 
suspension assay (Luminex) as described previously (17). Detailed information on the 
protocol, the confirmation method and assessment of sensitivity and specificity is 
given in Supplemental Material and Methods (10, 19, 20). 
 
Statistical methods 
Agreement between BKPyV/JCPyV qPCR and multiplex PCR was analyzed 
using a two-way contingency table and Altman scheme (almost perfect: kappa 1.00, 
very good: kappa 0.81-0.99, good: kappa 0.61–0.80, fair: kappa 0.21–0.40 and poor: 
kappa <0.20). The association between the detection rate non-BKPyV/JCPyV HPyVs 
and evidence for PVAN progression was analyzed using Fisher´s exact test. For all 
statistical tests, a two-sided p-value of <0.05 was considered statistically significant 
and GraphPad Prism version 5.0 software was used.  
 
Results 
Detection of BKPyV and JCPyV by qPCR 
Out of 400 plasma and 388 urine samples, BKPyV DNA was detected by 
quantitative PCR (qPCR) in 260 plasma and 305 urine samples and JCPyV in 67 
plasma and 170 urine samples. Eighty-three of the 99 KTRs (84%) particularly 
displayed one or more episodes of BKPyV DNAemia post-transplant (median BKPyV 
DNA load: 3.6x104 copies/ml, range: 1.0x102-1.5x109). Of these 83, 50 additionally 
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displayed JCPyV DNaemia at any time during follow-up (median viral load: 3.2x103 
copies/ml, range: 1.0x102-8.0x105). Two patients (2%) displayed JCPyV DNAemia 
alone. Fourteen out of the 99 KTRs (14%) did not display BKPyV or JCPyV detection, 
neither in urine nor in blood. Patient baseline characteristics did not significantly differ 
among these groups (Supplemental Table 1). 
 
Comparison of single and multiplex PCRs for BKPyV and JCPyV detection 
All samples quantified for BKPyV and JCPyV DNA by qPCR were retested with 
multiplex PCR. The comparative results are shown in Table 1. To evaluate the 
performance of multiplex PCR Cohen’s kappa values were calculated based on 
qPCRs positivity. Agreement between the two assays was good to very good (kappa 
for BKPyV in plasma=0.89, for BKPyV in urine=0.91, for JCPyV in plasma=0.76 and 
for JCPyV in urine=0.75). Discrepant test results mainly occurred at DNA loads 
<1x103 copies/mL. 
 
Detection of non-BKPyV/JCPyV HPyVs  
Newly discovered HPyVs (other than BKPyV and JCPyV) could be detected in 
a total of 21 of all 99 KTRs (21.2%). In total, 3 different non-BKPyV/JCPyV HPyVs 
were detected. As shown in Figure 1, Human Polyomavirus 9 (HPyV9) was detected 
in a blood sample from one patient and MCPyV was detected in 9 blood and 21 urine 
samples from a total 20 KTRs (Figure 2). In one of those 20 patients, TSPyV was 
detected in a subsequently acquired blood sample. 
The detection rates of MCPyV, HPyV9 and TSPyV in plasma samples were 
8.1% (8/99), 1.1% (1/99) and 1.1% (1/99) respectively. Viral DNA concentrations in 
plasma were low and were only found in patients who displayed BKPyV and/or JCPyV 
DNAemia during the follow-up. 
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MCPyV detection 
MCPyV was detected in 9 blood samples from 8 KTRs, in 2 patients exactly at 
the day of transplantation, in the remaining individuals between the 32nd and the 239th 
day post-transplant (Figure 2). The median MCPyV DNA load was 5.9x102 copies/mL 
(range: 1.2x102-1.4x103 copies/mL). MCPyV detection in plasma coincided with 
BKPyV DNAemia in 6 KTRs and with PVAN in one patient respectively. In one of 
these individuals MCPyV was detectable in blood 2 months prior to BKPyV DNAemia 
(patient #73, Figure 2). 
In urine, MCPyV DNA was detected in 16 KTRs (16.2%) with a median viral 
load of 6.3x102 copies /mL (range: 1.2x102-4.2x104 copies/mL). In contrast, to MCPyV 
detection in blood, MCPyV DNAuria occurred during the entire post-transplant follow-
up, ranging from the transplantation day to the 796th day post-transplant. Out of the 
21 episodes of MCPyV DNAuria, 9 occurred simultaneously with BKPyV DNAemia 
and 5 emerged when PVAN was diagnosed (Figure 2).  
In 6 cases MCPyV was detected in multiple blood and/or urine samples from 
the same patient respectively. As shown in Figure 2, one of these patients (patient 
#74) displayed persistent MCPyV DNA shedding in urine (with 4 positive samples over 
a period of 686 days) which started when PVAN developed and continued during 
subsequent and prolonged high-level BKPyV DNAemia. 
 
HPyV 9 and TSPyV detection 
HPyV9 DNA (3.4x103 copies/mL) was detected in a blood sample from a 27-
year-old male at the same time point when BKPyV DNA loads in urine and in blood 
peaked and PVAN was verified histologically (126th day post-transplant). In two 
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consecutive samples (obtained after 2 and 12 months), as well as in all corresponding 
urine samples, HPyV 9 was undetectable.  
Furthermore, TSPyV DNA was found in one blood sample from a 59-year-old 
male (patient #78, Figure 2) at the 32nd month post-transplant, who did not display 
BKPyV DNAemia at the same time, but had experienced a combined episode of 
MCPyV DNAuria and BKPyV DNAemia 111 days earlier. The TSPyV DNA load, 
however, was too low to be quantified.  
 
Detection rate of non-BKPyV/JCPyV HPyVs in relation to severity of BKPyV 
DNAemia  
Finally, we analyzed whether HPyV detection (other than BKPyV and JCPyV) 
differed among patients with BKPyV DNAemia in relation to the clinical severity of this 
DNAemia. Therefore, we grouped the 83 BKPyV DNAemic KTRs based on 
quantitative BKPyV DNA loads and PVAN evidence (Table 2). Nine-teen KTRs of our 
cohort only displayed peak DNA loads lower than 104 copes/ml during any BKPyV 
DNAemia episode. Decoy cell levels and incidence rates of a concurrent decrease of 
renal function were significantly lower in these KTRs than in patients with BKPyV DNA 
levels >104 copies/ml. BKPyV DNA loads exceeded 104 copies/ml in 45 KTRs, in 
whom significantly higher decoy cell levels and higher incidence rates of decreased 
renal function occurred, but no biopsy was performed during BKPyV DNAemia (Table 
2). In 19 KTRs, presence of PVAN was additionally confirmed in a biopsy (also see 
Supplemental Material and Methods), and these individuals displayed the highest 
BKPyV DNA loads, decoy cell levels and highest rates of a concurrent decrease of 
renal function (Table 2).  
As shown in Table 2, the detection rate of MCPyV in urine, but not in blood, 
was significantly higher during BKPyV DNAemia episodes in these 19 KTRs with 
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verified PVAN than in the other patients with BKPyV DNAemia (p=0.005). For the 
detection of non-BKPyV/JCPyV HPyVs in blood, there was no statistical evidence for 
such an association between progression of BKPyV replication and increased 
detection rates, and this applied to detection during or in absence of BKPyV DNAemia 
(Table 2). Of note, additional JCPyV DNAemia occurred more frequently in KTRs with 
high level BKPyV DNAemia (Table 2). 
 
Discussion 
In order to identify whether the newly discovered HPyVs occur more frequently 
in KTRs with clinically progressed BKPyV replication we performed a retrospective, 
comprehensive genoprevalence analysis of 13 HPyVs in a cohort of KTRs with and 
without high level BKPyV DNAemia, grouped by viral loads and histological evidence 
of PVAN. Although HPyV9 and MCPyV DNAemia frequently occurred during BKPyV 
DNAemia episodes and PVAN, we found no statistical evidence for an increased 
occurrence of the newly identified HPyVs in blood due to clinically manifest BKPyV 
replication. A higher detection rate of MCPyV DNAuria however, was observed in our 
cohort when patients developed PVAN.  
Indeed, to our knowledge, only one publication has described all 13 first-
detected HPyVs in longitudinal kidney transplantation cohort (21). In this previous 
study low detection frequencies of non-BKPyV/JCPyV HPyVs were reported. 
Recently, an analysis on the impact of HPyV9 and TSPyV coinfection on BKPyV 
DNAemia demonstrated a positive association between HPyV9 seropositivity and 
subsequent PVAN development, while TSPyV DNAemia was only detected in a small 
number of KTRs (22).  
With the aim of extending these existing findings, we focused on investigating 
HPyVs in a specifically selected KTR cohort with high-level BKPyV DNAemia and 
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PVAN and analyzed pairs of blood and urine samples. In agreement with previous 
data, we detected two newly discovered HPyVs, HPyV 9 and TSPyV in blood 
samples, respectively, confirming generally low detection frequencies of these viruses 
(20, 21). We detected MCPyV at higher frequencies in blood, but even more in urine 
samples. 
Of note, in our study cohort the detection rates of MCPyV in urine, but not in 
blood, were higher in patients with histologically verified PVAN than in patients with 
mere high level BKPyV DNAemia, and persistent MCPyV shedding with multiple 
positive urine samples was specifically observed in an individual with PVAN. Similar 
to our findings, previous studies reported that MCPyV viruria and occasionally 
prolonged shedding were detected in adult and pediatric KTRs (21, 23). Furthermore, 
Husseiny et al. found MCPy viruria in 30% of recipients, and that low-level shedding 
of MCPyV in urine occurred in immunosuppressed and immunocompetent subjects 
(24). Together with our data this indicates that MCPyV might persist in renal tubule or 
bladder epithelial cells and could reactivate similarly to BKPyV, although the primary 
latency site is not entirely elucidated (21). 
Another accordance with previous studies was that we detected non-BKPy/-
JCPyV HPyVs in blood at low DNA levels, with most of the viral DNAemia episodes 
occurring at a single time point mostly during the first 4 months post-transplant (21, 
23-26). This observation indicates that the early phase of high dose 
immunosuppression after transplantation could not only trigger BKPyV but also 
MCPyV reactivation (13, 15, 21). 
Indeed, we here initially applied a new multiplex method in a large cohort of 
KTRs, able to simultaneously assess 13 HPyVs with a single assay. Since qPCR was 
used for clinical routine surveillance of BKPyV and JCPyV replication, we were able 
to determine the inter-assay variability and found good agreement between the 
Jo
urn
al 
Pre
-pr
oo
f
 13 
multiplex assay and qPCR, which further validates the newly developed method. The 
detection limits for BKPyV and JCPyV were lower using qPCR, proposing that the 
multiplex assay is more suitable for screening studies for the full spectrum of HPyVs 
rather than clinical follow-up of BKPyV and JCPyV. 
Another interesting aspect of the current data, was that HPyV9 DNAemia 
occurred in one sample with a high BKPyV DNA load, obtained from a patient during 
an episode of histologically verified PVAN. A previous study first described the 
presence of HPyV9 in blood samples from KTRs; however, the prevalence in our 
study, was significantly lower than the original report (20). As noted, our multiplex 
assay displayed a lower sensitivity for BKPyV than qPCR; and divergent detection 
rates could be due to differences in primer sets and sample materials (21, 25). 
Notably, HPyV9 DNA was absent from the patient’s corresponding urine sample, as 
well as from all urine samples from the KTRs, suggesting that HPyV9 may not be 
excreted through the urinary tract at detectable levels.  
In summary, we systematically and comprehensively studied the 
genoprevalence of 13 HPyVs with a new assay in a cohort of KTRs with high-level 
BKPyV DNAemia and demonstrated that DNAemia of MCPyV and to a lesser extent 
of HPyV9 and TSPyV emerged with variable kinetics during post-transplant follow-up. 
MCPyV DNAuria, however, was detected in our cohort with a higher frequency in 
patients who in addition to BKPyV DNAemia also displayed histological evidence of 
PVAN. 
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Figure Legends 
 
Figure 1  
HPyV DNA in blood and urine in KTRs over time. The insert shows the logarithm of 
the MCPyV DNA copy number per mL (y) plotted against the ost transplantation time 
(x). A: HPyV in blood. The square box indicates BKPyV DNA, upwards triangle shows 
JCPyV DNA, ringed cross indicates MCPyV DNA, and downwards triangle is HPyV9 
DNA. In one patient TSPyV was detected by multiplex analysis, the DNA load, 
however, was too low to be quantified by qPCR and is therefore not shown. B: HPyV 
in urine. The square box indicates BKPyV DNA, upwards triangle shows JCPyV DNA, 
and ringed cross indicates MCPyV DNA.  
 
Figure 2  
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Patients with episodes of MCPyV DNA detection during the follow-up post-
transplantation. The logarithm of the MCPyV DNA copy number per mL is shown on 
the Y-axis, and day after the transplantation shown on the x-axis. Dashed lines 
separate individual patients. White and black bars indicate positive MCPyV findings 
in urine and in blood, respectively. Hash indicates a positive MCPyV DNA detection 
episode which coincided with BKPyV DNAemia. Stars indicate MCPyV DNA detection 
episodes which coincided with histological verification of PVAN. 
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Table 1. Comparison of BKPyV/JCPyV qPCR and multiplex PCR 
 
 
  qPCR 
M
u
lt
ip
le
x
 
P
C
R
 
 + - Total 
+ 237 0 237 
- 23 140 163 
 Total 260 140 400 
 
 
 
 
  qPCR 
M
u
lt
ip
le
x
 
P
C
R
 
 + - Total 
+ 45 0 44 
- 23 333 356 
 Total 67 333 400 
 
  qPCR 
M
u
lt
ip
le
x
 
P
C
R
 
 + - Total 
+ 302 8 310 
- 3 75 78 
 Total 305 83 388 
  qPCR 
M
u
lt
ip
le
x
 
P
C
R
 
 + - Total 
+ 125 0 125 
- 45 218 263 
 Total 170 218 388 
BKPyV in EDTA-plasma  
Kappa=0.88 
BKPyV in Urine 
Kappa=0.91 
JCPyV in EDTA-plasma 
Kappa=0.77 
JCPyV in Urine 
Kappa=0.76 
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Table 2: Non BKPyV/JCPyV HPyV detection in relation to clinical severity of most severe BKPyV DNAemia episode during follow-up 
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no BKPyV and 
JCPyV 
DNAemia 
BKPyV DNA load in blood 
Difference 
among the 
groups 
<104 copies/ml >104 copies/ml 
>104 copies/ml + 
histologically  
verified PVAN 
number of patients 14 19 45 19 
peak BKPyV 
DNAemia 
DNA load  
(median, range; 
copies/ml) 
- 
1.60x103, 
1.00x102-5.50x103 
3.90x104,  
1.00x102-1.00x107 
7.80x105,  
1.10x104- 1.50x109 
p<0.0001* 
decoy cells 
%  
(median, range) 
- 1, 0-80 70, 0-95 90, 60-99 p<0.0001* 
decrease of renal 
function ++ 
number of 
patients, % 
- 1/19, 5% 14/45, 31% 17/19, 89% p<0.0001** 
additional 
JCPyV DNAemia 
number of 
patients, % 
- 1/19, 5%  19/45, 42% 7/19, 37% p=0.001** 
DNA load  
(median. range; 
copies/ml) 
- 1.00x102 
1.80x103,  
1.00x102-8.00x105 
3.60x104,  
5.00x102-5.00x105 
p=0.018*** 
detection of non BKPyV/JCPyV HPyVs (in number of patients) 
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Abbreviations: BKPyV: BK Polyomavirus, JCPyV: JC polyomavirus, HPyV: Human Polyomavirus, eGFR: estimated glomerular filtration rate. PVAN: Polyomavirus associated nephropathy 
+ with respect to:(1) highest BKPyV DNA load in blood, (2) highest decoy cell level, (3) eventual decrease of eGFR and (4) eventual verification of PVAN by histology 
++ ≥15% decrease of eGFR. as compared to mean of the 3 preceding measurements 
* non-parametric Kruskall-Wallis t-test 
** Fisher´s exact test 
*** Mann-Whitney t-test 
 
during 
BKPyV/JCPyV 
DNAemia 
in urine - none 
3  
(MCPyV) 
6 
(all MCPyV) 
p=0.005** 
in blood - 
1  
(MCPyV) 
3 
(2xMCPyV. 1xHPyV9) 
3 
(all MCPyV) 
p=0.560** 
in absence of 
BKPyV/JCPyV 
DNAemia 
in urine 
1  
(MCPyV) 
3  
(all MCPyV) 
3 
(all MCPyV) 
none p=0.291** 
in blood none 
1  
(TSPyV) 
2 
(all MCPyV) 
none p=0.999** 
